Anders Österborg
Impact in
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Erythropoietin and Anemia Treatment
Papers in
- Genetics 117
- Chronic Lymphocytic Leukemia Research 117
- Hematology 58
- Multiple Myeloma Research and Treatments 35
- Erythropoietin and Anemia Treatment 22
- Co-authors
- Håkan Mellstedt (82 shared papers)Jeanette Lundin (40 shared papers)Matti Aapro (8 shared papers)Mahmood Jeddi‐Tehrani (17 shared papers)Eva K. Kimby (14 shared papers)Lotta Hansson (41 shared papers)Marzia Palma (24 shared papers)Carsten Bokemeyer (5 shared papers)
- Journals
- Blood (62 papers)British Journal of Haematology (20 papers)European Journal Of Haematology (12 papers)Haematologica (10 papers)Leukemia (8 papers)
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Anders Österborg
239 papers receiving 12.3k citations
Anders Österborg's Hit Papers
Peers
Comparison fields: 5 of 113
- Genetics 3.7k
- Hematology 2.5k
- Pathology and Forensic Medicine 2.6k
- Immunology 1.3k
- Oncology 1.1k
Countries citing papers authored by Anders Österborg
This map shows the geographic impact of Anders Österborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Österborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Österborg more than expected).
Fields of papers citing papers by Anders Österborg
This network shows the impact of papers produced by Anders Österborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Österborg. The network helps show where Anders Österborg may publish in the future.
Co-authors
The 25 scholars most cited alongside Anders Österborg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 243 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Hit paper breakdown → | 2006 | 1710 |
| 2 | 2010 | 476 | |
| 3 | 2002 | 414 | |
| 4 | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials | 1998 | 413 |
| 5 | Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia Hit paper breakdown → | 2022 | 334 |
| 6 | 2006 | 305 | |
| 7 | 2003 | 301 | |
| 8 | 2016 | 300 | |
| 9 | 2004 | 255 | |
| 10 | 2004 | 253 | |
| 11 | Outcomes of COVID-19 in patients with CLL: a multicenter international experience Hit paper breakdown → | 2020 | 253 |
| 12 | 2002 | 252 | |
| 13 | Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial Hit paper breakdown → | 2022 | 213 |
| 14 | 2021 | 185 | |
| 15 | 2010 | 178 | |
| 16 | 1998 | 173 | |
| 17 | Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities Hit paper breakdown → | 2022 | 171 |
| 18 | 1996 | 163 | |
| 19 | 2012 | 163 | |
| 20 | 2008 | 156 |
About Anders Österborg
Anders Österborg is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Infectious Diseases, having authored 243 papers that have together received 12.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (117 papers), Multiple Myeloma Research and Treatments (35 papers), Lymphoma Diagnosis and Treatment (25 papers), Erythropoietin and Anemia Treatment (22 papers), SARS-CoV-2 and COVID-19 Research (13 papers), Immunotherapy and Immune Responses (11 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (5 papers). The work is most often cited by research in Genetics (3.7k citations), Hematology (2.5k citations), Pathology and Forensic Medicine (2.6k citations), Immunology (1.3k citations) and Oncology (1.1k citations). Anders Österborg has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Håkan Mellstedt, Jeanette Lundin, Matti Aapro, Mahmood Jeddi‐Tehrani, Eva K. Kimby, Lotta Hansson, Marzia Palma, Carsten Bokemeyer, Lazzaro Repetto and Jan Foubert. Their work appears in journals such as Blood, British Journal of Haematology, European Journal Of Haematology, Haematologica and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.